I'm Susan Jabinsky, co-host of the Morning Filter podcast. Today, we're looking at some top value stocks to buy and hold for 2026. These stocks have a few things in common.For starters, they land on the value side of the Morning Star style box. They also appear on Morning Star's best companies to own list. These companies have carved out wide economic moes, have predictable cash flows, and are managed by teams with a history of making smart capital allocation decisions.And best of all, these stocks all look ...

Company Performance - Abbott's stock closed at $128.47, reflecting a +2.4% change from the previous day's closing price, outperforming the S&P 500's loss of 0.16% [1] - Over the past month, Abbott's shares have decreased by 3.93%, underperforming the Medical sector's gain of 1.12% and the S&P 500's loss of 0.21% [1] Upcoming Financial Results - Abbott's upcoming EPS is projected at $1.5, indicating an 11.94% increase compared to the same quarter of the previous year [2] - Revenue is expected to reach $11.79 billion, representing a 7.48% growth compared to the corresponding quarter of the prior year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $5.15 per share and revenue at $44.6 billion, reflecting changes of +10.28% and +6.33% respectively from the prior year [3] Analyst Estimates - Recent adjustments to analyst estimates for Abbott are important as they indicate changing near-term business trends, with upward revisions suggesting analysts' positivity towards the company's operations [4] - The consensus EPS projection has remained stable over the past 30 days, and Abbott currently holds a Zacks Rank of 3 (Hold) [6] Valuation Metrics - Abbott's Forward P/E ratio is 24.37, which is a premium compared to the industry average Forward P/E of 19.3 [6] - The company has a PEG ratio of 2.29, while the average PEG ratio for Medical - Products stocks is 1.92 [7] Industry Context - The Medical - Products industry, part of the Medical sector, has a Zacks Industry Rank of 165, placing it in the bottom 34% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

the president there taking a lot of questions and a very long pro conference on a whole range of topics. But the headline was really about the war between Gaza and Israel right now with a peace treaty and the president saying 28 hostage bodies uh remain in captivity but all hostages should be released on Monday. Let's go to Yamish Alendor who's at the White House.And Yamish, the the president says um Astroenica uh the drug company is sell drugs directly to Medicaid patients at the lowest price offered in an ...

Company Performance - Abbott's stock closed at $134.59, reflecting a +1.2% increase from the previous day, outperforming the S&P 500's gain of 0.01% [1] - Over the past month, Abbott's shares have appreciated by 0.14%, underperforming the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83% [1] Upcoming Earnings - Abbott is set to release its earnings report on October 15, 2025, with an expected EPS of $1.3, indicating a 7.44% growth year-over-year [2] - The consensus estimate for revenue is $11.42 billion, reflecting a 7.4% increase compared to the same quarter last year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates project earnings of $5.15 per share and revenue of $44.68 billion, representing increases of +10.28% and +6.5% respectively from the previous year [3] - Recent changes to analyst estimates for Abbott indicate evolving short-term business trends, with positive revisions suggesting analysts' confidence in the company's performance [3] Valuation Metrics - Abbott's current Forward P/E ratio is 25.83, which is a premium compared to the industry average of 18.31 [6] - The PEG ratio for Abbott stands at 2.52, compared to the industry average PEG ratio of 2.27 [6] Industry Context - The Medical - Products industry, which includes Abbott, has a Zacks Industry Rank of 77, placing it in the top 32% of over 250 industries [7] - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [7]

President Trump unveiled a direct-to-consumer website for Americans to buy drugs, dubbed TrumpRx, and said Pfizer plans to offer some of its drugs on the site at a reduced rate. https://t.co/vGSnodYufe ...

Pfizer to offer cheaper drugs via Trump's website https://t.co/oVijCtwJ3t ...

Exclusive: President Trump unveiled a direct-to-consumer website for Americans to buy drugs, dubbed TrumpRx, and announced that Pfizer plans to offer some of its drugs on the site at a reduced rate https://t.co/l5w5eV8M53 ...

Pfizer to sell drugs at lower prices to US Medicaid under Trump’s ‘most favored nations’ plan, the Washington Post reports https://t.co/lWk28a2x8C ...

Tariffs on Various Products - President Trump announced a 100% tariff on brand name or patented pharmaceutical products starting October 1st, unless manufacturers establish a plant in the US [1] - A 50% tariff will be imposed on kitchen cabinets, bathroom vanities, and related products, along with a 30% tariff on upholstered furniture, effective next week [2] - Additionally, a 25% tariff on imported heavy trucks is being introduced, framed as a national security measure to support American truckers [2] Impact on Costs and Prices - Critics argue that these tariffs could increase costs for businesses and consumers, with previous tariffs on steel, aluminum, and copper already raising expenses for US truck manufacturers [3] - Furniture prices have also seen significant increases due to earlier tariffs, with living and dining room pieces rising nearly 10% over the past year according to the Bureau of Labor Statistics [3][4]

Group 1 - U.S. stock futures showed volatility following President Trump's announcement of new tariffs on drugs, trucks, and furniture [1] - The market reaction to the tariff news was relatively calm, indicating resilience among investors [1]